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Abstract
Background: High-dose intravenous immune globulins (IVIg) are frequently used in refractory juvenile dermatomyositis
(JDM) but are often poorly tolerated. High-dose recombinant human hyaluronidase-facilitated subcutaneous
immune globulins (fSCIg) allow the administration of much higher doses of immune globulins than conventional
subcutaneous immune globulin therapy and may be an alternative to IVIg. The safety and efficacy of fSCIg
therapy in JDM is unknown.
Case Presentation: In this retrospective case series, five patients with steroid-refractory severe JDM were treated
with high-dose fSCIg due to IVIg adverse effects (severe headaches, nausea, vomiting, difficult venous access).
Peak serum IgG levels, muscle enzymes, the childhood myositis assessment scale and adverse effects were
retrieved for at least 6 months following intiation of fSCIg. Data were analyzed by descriptive statistics.
Patients initially received fSCIg 1 g/kg every 14 days, resulting in median IgG peak levels of 1901 mg/dl (1606–
2719 mg/dl), compared to median IgG peak and trough levels while previously receiving IVIg of 2741 mg/dl (2429–
2849 mg/dl) and 1351 mg/dl (1156–1710 mg/dl). Additional antirheumatic therapies consisted of low-dose
glucocorticoid therapy, methotrexate, mycophenolate mofetil and/or rituximab. Two patients maintained clinically
inactive disease and three patients had only a partial treatment response. In the three patients with partial
treatment response, fSCIg 1 g/kg was then given on days 1 and 6 of every 28-day cycle resulting in IgG peak
levels of between 2300–2846 mg/dl (previously 1606–1901 mg/dl on the biweekly regimen), resulting in clinically
inactive disease in two of the three patients. There were no relevant adverse effects that limited continuation of
fSCIg treatment.
Conclusions: High-dose fSCIg is well-tolerated in patients with JDM and high peak serum IgG levels can be
achieved which may be important for treatment success. High-dose fSCIg may therefore be an alternative to
high-dose IVIg and deserves further study.
Trial registration: This is a case series and data were retrospectively registered.
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Background
Juvenile dermatomyositis (JDM) is a severe inflammatory
myopathy characterized by vasculopathy affecting skin,
muscle and sometimes internal organs [1]. While mortality
is low with contemporary treatment, morbidities, such as
dystrophic calcification, contractures and muscle weakness
still cause a substantial long-term disease burden [2, 3].
However, little high-quality data from clinical trials exists
to guide treatment decisions and treatment is mostly
guided by expert opinion and consensus treatment proto-
cols [1, 4–6]. There is evidence that the routine treatment
of moderately-severe JDM should include high-dose ste-
roids and methotrexate [7]. Additional steroid-sparing im-
munomodulatory therapies are often employed, especially
including intravenous immune globulins (IVIg), hydroxy-
chloroquine, cyclosporine, azathioprine, mycophenolate
mofetil and rituximab. Even though randomized clinical
trials for IVIg in JDM are lacking, it appears to be highly
effective in severe or refractory JDM [8, 9]. Typically, the
administration of up to 2 g per kg and month of IVIg are
required to achieve treatment success, since anti-
inflammatory efficacy may depend on peak serum immune
globulin (Ig)G levels [10, 11]. High-dose IVIg treatment
causes adverse effects in 5-10 % of patients [11], including
severe headaches, nausea, vomiting, aseptic meningitis,
thrombosis and venous access may be difficult over time
whereas subcutaneous Ig (SCIg) treatment is usually well-
tolerated [12]. However, since the extracellular matrix
limits subcutaneous bulk fluid flow, the maximal volume
infusible by standard SCIg in one site is 30 ml, effectively
limiting the amount of Ig that can be applied in a single
treatment and, thus, its utility as an anti-inflammatory
therapy. By means of facilitating SCIg with recombinant
human hyaluronidase (rHUPH20) (fSCIg), a 20-fold higher
volume of up to 600 ml fSCIg (equaling 60 g of Ig) can be
administered at one site [13]. Cleaving hyaluronic acid in-
creases permeability of the subcutaneous tissue markedly.
Since rHUPH20 is not available systemically, short-acting
and non-immunogenic, and since tissue hyaluronic acid is
rapidly resynthesized, there are typically no short-term or
long-term adverse effects. Regarding the pharmacokinetics
of fSCIg, the median time to reach peak serum IgG levels
is five days [13]. fSCIg is currently approved for the use in
patients with primary immunodeficiency disorders older
than 18 years of age but has been tested in children older
than two years of age. The safety and efficacy of high-dose
fSCIg therapy in JDM is unknown.
Case Presentation
Patients
Five patients with moderately severe or severe and refrac-
tory definitive JDM who had initially received IVIg were
treated with fSCIg for at least six months were identified
at the German Center for Pediatric and Adolescent
Rheumatology in Garmisch-Partenkirchen between Janu-
ary 2012 and December 2015 [5]. Overall, 42 patients with
JDM were treated at the center in that time frame, of
whom 26 had received IVIg (62 %). Informed consent was
obtained from all patients and guardians. Patient
demographics, myositis-specific autoantibodies, clinical
phenotype, disease severity [5], concurrent antirheumatic
therapy and reasons for initiation of/switching to fSCIg
treatment are shown in Table 1.
Administration of subcutaneous immune globulins
Patients 1–4 started fSCIg treatment 4–6 weeks after the
last IVIg dose, and patient 5, who had not recently re-
ceived IVIg, started fSCIg after a disease flare. All patients
received high-dose fSCIg with recombinant human hyal-
uronidase (HyQvia, Baxalta, Unterschleißheim, Germany)
between 1.7 to 2 g/kg per month (maximally 70 g per
month) divided into two doses. Patients each received two
inpatient training fSCIg treatments (first 0.3 g/kg, then
1 g/kg). Following hospital discharge, patients and parents
received one or two fSCIg treatments at home guided by a
nurse practitioner especially trained in the application of
fSCIg. Eutectic mixture of local anesthetics was applied
prior to the subcutaneous infusions and fSCIg was admin-
istered according to the manufacturer’s instruction with
maximal infusion rates of 160 ml/h (body weight <40 kg).
Each individual fSCIg administration took on average
three to four hours. For three patients, the regimen was
later switched to two monthly fSCIg doses five days apart,
i.e., the same monthly total dose was given divided into
two doses at days 1 and 6 of each 28-day cycle.
Data collection and analysis
As part of the clinical routine at the center multiple clin-
ical and laboratory parameters are collected prospectively
for all patients with JDM. For this retrospective analysis,
the following clinical and laboratory parameters were re-
trieved for analysis: serum IgG levels, muscle enzyme
levels, childhood myositis assessment scale (CMAS) score,
physician global assessment of disease activity, and poten-
tial treatment adverse effects. Data were analyzed using
descriptive statistics.
Serum IgG levels
For the various time points of measuring serum IgG levels
(before Ig therapy, peak/trough during IVIg, and peak dur-
ing SCIg) up to nine different data point were available and
mean IgG levels were calculated for each patient and time
point. Overall, fSCIg treatment every 14 days resulted in
median IgG peak levels, measured five days after adminis-
tration, of 1901 mg/dl (range 1606–2719 mg/dl), compared
to median IgG peak (one day after dose) and trough levels
(28 days after dose) while previously receiving IVIg 2 g per
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Table 1 Patient demographics, current antirheumatic therapy, reasons for initiation of subcutaneous immune globulins, and disease course following fSCIg therapy
Patient Sex, age, age at
disease onset, body
weight
Clinical phenotype and disease





Previous or concurrent antirheumatic
treatments
Reason for initiation of fSCIg
instead of IVIg, CMAS at time
of fSCIg initiation
Disease course following initiation
of fSCIg
1 Male, 11 years,
9 years at disease
onset, 35 kg









IVIg (60 g/month), fSCIg (70 g/month),
PDN 0.125 mg/kg/day, MTX 15 mg/
m2/week, HCQ
IVIg adverse effects (headaches,
nausea and vomiting), needle
phobia
CMAS 51
Within 3 months mild deterioration
of CMAS (49 instead of 51);
resolution after switching to fSCIg
5 days apart
2 Female, 10 years,
8 years at disease
onset, 35 kg









IVIg (70 g/month), fSCIg (70 g/month),
PDN 0.21 mg/kg/day, MMF 1200 mg/
m2/d, MTX 15 mg/m2/week, RTX
(status post 375 mg/m2 ×4), CYC
(status post 6 × 750 mg/m2)
IVIg adverse effects (headaches),
difficult peripheral venous
access with port-a-cath
CMAS not interpretable due to
severity of contractures
Stable mild residual disease activity
even after switching to fSCIg 5 days
apart
3 Female, 7 years,
5 years at disease
onset, 20 kg







IVIg (40 g/month), fSCIg (40 g/month),
PDN 0.125 mg/kg/day, MMF 1200 mg/
m2/d, MTX 15 mg/m2/week
RTX (status post 375 mg/m2 × 4
[first cycle], 750 mg/m2 × 1 [second cycle])
IVIg adverse effects (headaches,
nausea and vomiting), needle
phobia
CMAS 52
Maintenance of clinically inactive
disease; CMAS 52; fSCIg continued
biweekly
4 Male, 12 years,
8 years at disease
onset, 35 kg
Classic, moderately severe







IVIg (35 g/month), fSCIg (60 g/month)
PDN 0.07 mg/kg/day, MMF 1200 mg/
m2/d, Colchicin
IVIg adverse effects (headaches,
nausea and vomiting), needle
phobia, residual disease activity
with insufficient IVIg dose
CMAS 52
Maintenance of clinically inactive
disease; CMAS 52; calcinosis
decreasing; fSCIg continued
biweekly
5 Female, 8 years,
5 years at disease
onset, 20 kg









IVIG (40 g/month), fSCIg (50 g/month)
PDN 0.19 mg/kg/day, MMF 600 mg/
m2/d (diarrhea with higher doses),
MTX 15 mg/m2/week
IVIg adverse effects (headaches,
nausea and vomiting), needle
phobia
CMAS 46
Improvement but residual, mild
proximal muscle weakness;
normal muscle strength (inactive
disease) after switching to fSCIg
5 days apart; CMAS 50; further
PDN reduction
Abbreviations: CYC cyclophosphamide, IVIg intravenous immune globulins, fSCIg subcutaneous immune globulins facilitated by recombinant human hyaluronidase, MMF mycophenolate mofetil, MSA myositis-specific
antibodies, MTX methotrexate, PDN prednisolone, RTX rituximab











kg and month of 2741 mg/dl (range 2429–2849 mg/dl)
and 1351 mg/dl (1156–1710 mg/dl), respectively. In order
to achieve higher peak serum levels and improved immu-
nomodulatory efficacy, for three patients the fSCIg admin-
istration was switched to two monthly doses five days
apart (i.e., days 1 and 6 of each 28-day cycle). Following
fSCIg 1 g/kg on days 1 and 6, IgG serum levels on day 11
showed much increased IgG serum levels of 2846 mg/dl
(up from 1901 mg/dl), 2300 mg/dl (up from 1774 mg/dl),
and 2757 mg/dl (up from 1606 mg/dl). Individual levels
and courses are also shown in Fig. 1.
Disease activity
Muscle enzymes remained stable and within normal
limits. Patient 1 experienced mild worsening of the CMAS
(from 51 to 49), which improved again when switched to
fSCIg five days apart. Patient 2 had mild, stable residual
disease despite switching to fSCIg five days apart. Patients
3 and 4 maintained clinically inactive disease and kept
fSCIg 14 days apart. Patient 5 had resolution of skin
disease but mild residual muscle weakness with fSCIg
every 14 days which resolved after switching to fSCIg
five days apart.
Subcutaneous immune globulin administration and
monitoring for adverse effects
During and after fSCIg administration, the patients de-
veloped a localized subcutaneous pocket which resolved
within 24 h. One patient (Patient 5) had transient mild
headaches following administration of SCIg and a minor
local site reaction. None of the patients required
premedications (which all had required while receiving
IVIg). There were no incidences of treatment abortion
due to adverse effects. In three patients fSCIg five or
14 days apart was tolerated equally well. There was no
evidence of dystrophic calcification at the site of fSCIg
administration or elsewhere. All five patients reported
that they strongly preferred treatment with fSCIg over
IVIg, mostly due to the lack of adverse effects and the
avoidance of hospitalization for i.v. therapy.
Conclusions
This is, to our knowledge, the first report on the treatment
of severe refractory JDM with high-dose fSCIg. The appli-
cation of standard preparations of SCIg (without recom-
binant human hyaluronidase) in moderately severe JDM
(up to 1 g/kg and month) and refractory adult DM (up to
0.8 g/kg and month) resulting in improved quality of life
has been reported previously [14–16]. While standard
SCIg is typically applied between one and three times
weekly (in clinical practice maximally 56 g per month),
fSCIg may be applied less frequently, e.g., once monthly in
case of primary immunodeficiency, since it shows a better
bioavailability and in addition allows administration of up
to 120 g of Ig per month [13]. We demonstrated that the
administration of two doses of fSCIg separated by five
days for a total dose of 2 g/kg and month results in peak
serum IgG levels similar to those achieved by regular
high-dose IVIg treatment but not by conventional SCIg
treatment. It is suggested that high peak serum IgG levels
may be necessary for immune modulatory efficacy of Ig
therapy [10, 11]. We were able to avoid premedication
before IgG application and used oral corticosteroids
sparingly to avoid long-term steroid adverse effects.
High-dose fSCIg therapy was well tolerated by our pa-
tients and even when given five days apart producing
high IgG serum levels, we did not observe any relevant
local or systemic adverse effects. Specifically, there was no
evidence of increased local inflammation or dystrophic
calcification at the administration sites and no evidence of
aseptic meningitis or severe headaches. While high-dose
IVIg treatment typically requires hospitalization and
intravenous access, fSCIg can be administered without
difficulty at home and may therefore be both time- and
cost-saving [13, 17].
Our report is limited by the fact that this is a retro-
spective analysis of a small cohort of patients so that the
assessment of treatment efficacy is very limited.
In summary, high-dose fSCIg therapy may be an attract-
ive treatment option for patients with moderately severe or
severe refractory JDM as a remission maintenance treat-
ment and potentially also as a remission induction therapy
in case of IVIg intolerance, IgA deficiency or difficult ven-
ous access, in order to improve quality of life (avoiding
hospital admissions) and to reduce cost of treatment.
Fig. 1 IgG levels before initiation of Ig therapy, peak and trough
serum IgG levels (during high-dose IVIg therapy) and peak levels
during SCIg therapy. Values represent mean values and error bars
standard deviation (if multiple measurements are available).
The dashed lines represent the upper and lower limit of the
normal range
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Generally, the use of IVIg or fSCIg in JDM may allow re-
duction of steroid use. Further formal testing of efficacy
and safety by means of prospective clinical trials is
desirable.
Abbreviations
CMAS: Childhood myositis assessment scale; fSCIg: Hyaluronidase-facilitated
subcutaneous immune globulins; Ig: Immune globulin; IVIg: Intravenous
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